Company intelligence / Profile preview

OcuNexus Therapeutics

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

OcuNexus Therapeutics is a clinical-stage biopharmaceutical company developing therapies that modulate the inflammasome pathway by targeting the Connexin43 hemichannel. Its lead asset, lufepirsen (Nexagon), an antisense oligonucleotide, is in Phase II/III trials for corneal injuries and has orphan drug designation. The company also develops small molecule modulators for ophthalmic and renal indications such as dry AMD, diabetic retinopathy, and diabetic nephropathy. Clinical data suggest efficacy in reducing inflammation and tissue damage across multiple tissue types.[2][3][4][5]

Therapeutic areas: OphthalmologyNephrology
Modalities: Small moleculesAntisense oligonucleotides (e.g., lufepirsen/Nexagon)[5]
Industry: Biotech

Partnerships

Eyevance Pharmaceuticals listed as a developer of lufepirsen alongside OcuNexus.[5]

Beyond the preview

Go deeper on OcuNexus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OcuNexus Therapeutics.